Germany-based Medigene has announced an organizational realignment, cutting its workforce and refocusing R&D on its most promising off-the-shelf TCR-guided therapies.
According to Medigene, the re-org will include a workforce reduction of approximately 40% effective in 2025 as well as "other cost-reducing measures in line with the refocused R&D activities."
Specifically, the company will temporarily delay the start of the phase 2 trial for its IND-approved lead TCR-T therapy, MDG1015. MDG1015 is a first-in-class, third-generation T cell receptor-engineered T cell therapy targeting NY-ESO-1/LAGE-1a. By co-expressing the costimulatory switch protein PD1-41BB, the therapy is designed to address a significant unmet medical need in the treatment of solid tumors.
Medigene plans to pause all further development of other autologous cell therapy programs, while seeking future financing and partnerships to re-initiate further development. This includes MDG2021 (targeting KRAS G12D with HLA-A*11), MDG2011 (targeting KRAS G12V with HLA-A*11) and MDG2012.
The biotech's obligations to existing partners — which includes WuXi Biologics and BioNTech — will remain unaffected.
Subscribe to our e-Newsletters
Stay up to date with news, articles and insights relevant to cell and gene therapy development and manufacturing. Plus, get special offers from Cell & Gene Therapy Review delivered right to your inbox!
Sign up now!